Selective oestrogen degraders, or Serds, remain in focus as a key period for reporting clinical data approaches.
Upon review Pepaxto beats Pomalyst on progression-free survival, but new overall survival data trigger clinical hold and threaten the programme.
And four other potential targets that could make sense for the beleaguered group.
Biopharma scores a $5bn quarter as another big year builds for venture financing.
The third quarter will see important data for Travere, Radius and Sio Gene, among other small developers.